Market capitalization | €1.51b |
Enterprise Value | €1.67b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.15 |
P/S ratio (TTM) P/S ratio | 1.94 |
P/B ratio (TTM) P/B ratio | 1.56 |
Revenue (TTM) Revenue | €777.05m |
EBIT (operating result TTM) EBIT | €-135.27m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
12 Analysts have issued a Evotec forecast:
12 Analysts have issued a Evotec forecast:
Sep '24 |
+/-
%
|
||
Revenue | 777 777 |
3%
3%
|
|
Gross Profit | 106 106 |
39%
39%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -135 -135 |
130%
130%
|
Net Profit | -171 -171 |
2%
2%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Head office | Germany |
CEO | Christian Wojczewski |
Employees | 5,000 |
Founded | 1993 |
Website | evotec.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.